---
trial_id: 819
discovery_date: 2022-05-15 20:21:08.582947
date: 2022-05-15 20:21:08.582947
title: "A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro..."
summary: |
  <p>EudraCT Number: 2012-003056-36<br />Sponsor Protocol Number: CBAF312A2304<br />Sponsor Name: Novartis Pharma Services AG<br />Start Date: 2012-10-31<br />Medical condition: Secondary progressive multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/IE">IE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/CZ">CZ</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/SK">SK</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/NL">NL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/SE">SE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/IT">IT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/LV">LV</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/GR">GR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/EE">EE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/BE">BE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/FR">FR</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003056-36'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2012-003056-36<br />Sponsor Protocol Number: CBAF312A2304<br />Sponsor Name: Novartis Pharma Services AG<br />Start Date: 2012-10-31<br />Medical condition: Secondary progressive multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/IE">IE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/CZ">CZ</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/SK">SK</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/NL">NL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/SE">SE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/IT">IT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/LV">LV</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/GR">GR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/EE">EE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/BE">BE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/FR">FR</a> (Ongoing)</p>